

Francesco Mannelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9484313/publications.pdf>

Version: 2024-02-01

63
papers

2,466
citations

257101

24
h-index

205818

48
g-index

64
all docs

64
docs citations

64
times ranked

3033
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. <i>Blood Advances</i> , 2022, 6, 373-375.	2.5	34
2	<i>ASXL1</i> mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. <i>Blood Advances</i> , 2022, 6, 2927-2931.	2.5	20
3	Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. <i>American Journal of Hematology</i> , 2022, 97, 846-855.	2.0	9
4	Concomitant <i>JAK2</i> mutated myeloproliferative neoplasms and hereditary hemochromatosis. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 999-1000.	0.7	1
5	<i>SF3B1</i> mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	9
6	Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis. <i>Annals of Hematology</i> , 2021, 100, 337-344.	0.8	3
7	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. <i>Leukemia</i> , 2021, 35, 1121-1133.	3.3	61
8	<i>BRAF</i> V600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma. <i>Tumori</i> , 2021, 107, NP28-NP32.	0.6	0
9	Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis. <i>American Journal of Hematology</i> , 2021, 96, 749-754.	2.0	3
10	Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. <i>British Journal of Haematology</i> , 2021, 193, 845-848.	1.2	6
11	Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. <i>Leukemia</i> , 2021, 35, 3455-3465.	3.3	25
12	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. <i>American Journal of Hematology</i> , 2021, 96, 781-789.	2.0	46
13	AMELIORATE: early intensification in <i>FLT3</i> -mutated acute myeloid leukemia based on peripheral blast clearance – MYNERVA-GIMEMA AML1919 trial. <i>Future Oncology</i> , 2021, 17, 3787-3796.	1.1	0
14	Acute Myeloid Leukemia Evolving from Myeloproliferative Neoplasms: Many Sides of a Challenging Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 436.	1.0	12
15	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. <i>Haematologica</i> , 2021, 106, 2578-2587.	1.7	15
16	Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of <i>PDGFR1±</i> , <i>PDGFR2</i> , <i>FGFR1</i> or <i>PCM1-JAK2</i> . <i>Biomarker Research</i> , 2021, 9, 83.	2.8	1
17	<i>JAK2V617F</i> variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. <i>Blood Cancer Journal</i> , 2021, 11, 199.	2.8	47
18	Characteristics and clinical correlates of <i>NFE2</i> mutations in chronic Myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2020, 95, E23-E26.	2.0	8

#	ARTICLE	IF	CITATIONS
19	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020, 95, 156-166.	2.0	53
20	Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1304-1313.	2.0	1
21	Collision tumor between a spinal schwannoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: case report and review of the literature. <i>British Journal of Neurosurgery</i> , 2020, , 1-3.	0.4	0
22	Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category. <i>Cancers</i> , 2020, 12, 3196.	1.7	4
23	Primary analysis of JUMP, a phase 3b, expanded access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. <i>British Journal of Haematology</i> , 2020, 189, 888-903.	1.2	61
24	Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. <i>Blood Cancer Journal</i> , 2020, 10, 21.	2.8	35
25	Health technology assessment-based approach to flow cytometric immunophenotyping of acute leukemias: a literature classification. <i>Tumori</i> , 2020, 106, 249-256.	0.6	0
26	Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. <i>Clinical and Experimental Medicine</i> , 2020, 20, 313-320.	1.9	5
27	A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease. <i>American Journal of Hematology</i> , 2020, 95, 1622-1624.	2.0	1
28	Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. <i>Blood Advances</i> , 2020, 4, 301-311.	2.5	8
29	Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. <i>Hematological Oncology</i> , 2019, 37, 628-633.	0.8	3
30	Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. <i>American Journal of Hematology</i> , 2019, 94, E239-E242.	2.0	3
31	Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. <i>Blood</i> , 2019, 133, 2802-2808.	0.6	12
32	Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis. <i>American Journal of Hematology</i> , 2019, 94, 845-852.	2.0	5
33	A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases. <i>Hematological Oncology</i> , 2019, 37, 205-211.	0.8	2
34	Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data. <i>Bioinformatics</i> , 2019, 35, 4213-4221.	1.8	15
35	Validation of the Mayo alliance prognostic system for mastocytosis. <i>Blood Cancer Journal</i> , 2019, 9, 18.	2.8	6
36	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. <i>Leukemia</i> , 2018, 32, 1631-1642.	3.3	213

#	ARTICLE	IF	CITATIONS
37	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. <i>Leukemia</i> , 2018, 32, 1200-1210.	3.3	101
38	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018, 36, 310-318.	0.8	373
39	Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. <i>Blood Cancer Journal</i> , 2018, 8, 122.	2.8	25
40	Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey. <i>Journal of Blood Medicine</i> , 2018, Volume 10, 21-27.	0.7	2
41	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. <i>Blood Advances</i> , 2018, 2, 2964-2972.	2.5	68
42	<i>CEBPA</i> double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. <i>Haematologica</i> , 2017, 102, 529-540.	1.7	61
43	A life-threatening ruxolitinib discontinuation syndrome. <i>American Journal of Hematology</i> , 2017, 92, 833-838.	2.0	38
44	Immunophenotyping of Acute Leukemias – From Biology to Clinical Application. , 2016, , .		3
45	Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1983-1987.	2.0	77
46	Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia. <i>Experimental Hematology</i> , 2015, 43, 869-879.e22.	0.2	4
47	Levels of Minimal Residual Disease Prior to Transplant Influence Outcome of Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 4374-4374.	0.6	0
48	CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. , 2014, 86, 340-349.		11
49	CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. , 2014, , n/a-n/a.		19
50	A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 71-81.	0.7	7
51	Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. <i>Haematologica</i> , 2013, 98, 239-246.	1.7	268
52	Diagnosis of a T-lineage acute lymphoblastic leukemia through digitalized cell analysis of the pleural effusion. <i>International Medical Case Reports Journal</i> , 2013, 6, 77.	0.3	0
53	CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. <i>Haematologica</i> , 2012, 97, 568-571.	1.7	25
54	Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. <i>Blood</i> , 2012, 120, 3222-3228.	0.6	85

#	ARTICLE	IF	CITATIONS
55	Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. <i>American Journal of Hematology</i> , 2012, 87, 1047-1051.	2.0	26
56	Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. <i>Haematologica</i> , 2010, 95, 833-836.	1.7	34
57	Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00. <i>Journal of Clinical Oncology</i> , 2010, 28, 3644-3652.	0.8	250
58	Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: The crucial role of PTEN. <i>Experimental Hematology</i> , 2009, 37, 1176-1185.e21.	0.2	17
59	No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. <i>Leukemia</i> , 2008, 22, 669-671.	3.3	7
60	Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. <i>Blood</i> , 2008, 111, 1746-1747.	0.6	25
61	Molecular Profiling of CD34+ Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1). <i>Stem Cells</i> , 2007, 25, 165-173.	1.4	111
62	Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. <i>British Journal of Haematology</i> , 2006, 134, 54-57.	1.2	50
63	The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. <i>Leukemia</i> , 2006, 20, 2074-2076.	3.3	51